Drug Approval | November 19, 2022
Eugia Pharma receives USFDA approval for Amphotericin B Liposome for Injection
The product is expected to be launched by Q4 FY23.
The product is expected to be launched by Q4 FY23.
The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
Subscribe To Our Newsletter & Stay Updated
